FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to a peptide, a peptide mimetic or an amino acid derivative, which contain di-substituted β-amino acid, wherein each of substituting group in the β-amino acid, which can be identical or different, contains at least 7 non-hydrogen atoms, is lipophilic and contains at least one cyclic group; one or more cyclic groups in the substituting group can be bound or condensed with one or more numbers of cyclic groups in the other substituting groups, and when the cyclic groups are fused so that an aggregate total number of non-hydrogen atoms for these two substituting groups makes at least 12, wherein the above peptide, peptide mimetic or amino acid derivative consist of 1-4 amino acids or length-equivalent sub-units.
EFFECT: preparing the peptide, peptide mimetic or amino acid derivative, which contain the di-substituted β-amino acid.
17 cl, 4 dwg, 10 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC PEPTIDES | 2010 |
|
RU2676713C2 |
| NONAPEPTIDE WITH ANTITUMOUR ACTIVITY | 2009 |
|
RU2503685C2 |
| NOVEL SYNTHETIC PEPTIDES AND USE THEREOF | 2012 |
|
RU2596393C2 |
| ANTIBIOTIC PEPTIDES | 2008 |
|
RU2472805C2 |
| PEPTIDES, DETACHED FROM HUMAN LACTOFERRIN, AND USE THEREOF | 2012 |
|
RU2593757C2 |
| METHOD OF PRODUCING PEPTIDES OR PROTEINS OR PEPTIDOMIMETICS | 2020 |
|
RU2828026C2 |
| CYCLIC ANTIMICROBIAL PEPTIDES | 2006 |
|
RU2463308C2 |
| GLUCAGON ANALOGUES, POSSESSING HIGHER SOLUBILITY AND STABILITY IN BUFFERS WITH PHYSIOLOGICAL Ph VALUES | 2009 |
|
RU2560254C2 |
| MUC-1 PROTEIN CYTOPLASMIC DOMAIN PEPTIDES AS CANCER INHIBITORS | 2009 |
|
RU2539832C2 |
| IMIDAZOPYRIDINE DERIVATIVE AND PHARMACEUTICAL PREPARATION CONTAINING IT AS AN ACTIVE INGREDIENT | 2020 |
|
RU2810973C2 |
